Atrium Therapeutics to Present Nonclinical PRKAG2 Data at AHA Sessions
The company says a mouse surrogate of its investigational therapy reversed cardiac glycogen buildup and improved other PRKAG2 syndrome features.
Related stories
Enerjisa Enerji Q3 net profit rises to 3.8 billion lira
Net profit was 958.7 million lira a year earlier.
M impact | EQUITY | Nov 02, 2026, 03:44 PM UTC
Greece Agrees to Acquire Up to Six Embraer KC-390 Jets
Greece agreed to acquire up to six KC-390 Millennium jets from Embraer.
M impact | EQUITY | Nov 02, 2026, 03:41 PM UTC
Cipher Digital Shares Fall After Third-Quarter Revenue Miss
Cipher Digital shares fell Monday morning after the company reported third-quarter revenue below estimates. Bitcoin mining remained the majority of revenue.
M impact | EQUITY | Nov 02, 2026, 03:41 PM UTC
Enerjisa Enerji reports Q3 revenue
Revenue was lower than in the same period last year.
M impact | EQUITY | Nov 02, 2026, 03:40 PM UTC
Enerjisa Enerji Reports Q3 Revenue of 75.8 Billion Lira
Q3 revenue was 75.8 billion lira, versus 78.8 billion lira a year earlier.
M impact | EQUITY | Nov 02, 2026, 03:40 PM UTC
Reliance Rally and LTCG Rollback Proposal Lift Indian Stocks Nearly 2%
Reliance Industries shares had their best day since 2020, while optimism about a possible rollback of long-term capital gains tax for foreign investors accompanied gains of nearly
M impact | EQUITY | Nov 02, 2026, 03:40 PM UTC